Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091570 | 0.88 | P2RX3 (0.45) | LMNAMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL3088330 | 0.84 | TP53 (0.46) | LMNACCR2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL23630652 | 0.83 | ALOX5AP (0.49) | TBXA2RMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3094641 | 0.80 | FFAR1 (0.56) | CYP3A4CYP2C9PTGS1FFAR1 | |
| SCHEMBL3095854 | 0.79 | CCR2 (0.43) | LMNATBXA2RCCR2MAPTMEN1 | |
| SCHEMBL3095865 | 0.79 | CCR2 (0.43) | LMNATBXA2RCCR2MAPTMEN1 | |
| SCHEMBL23270754 | 0.78 | TBXA2R (0.41) | TBXA2RALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9959514 | 0.78 | TP53 (0.44) | LMNAMAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3096637 | 0.77 | MAPT (0.52) | LMNACCR2MAPTMEN1ALDH1A1 | |
| SCHEMBL3103070 | 0.77 | ALDH1A1 (0.40) | LMNACCR2MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933842-B1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | PANMIRA PHARMACEUTICALS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795274-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405302-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| WO-2007047207-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227807-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | LMNA 2110/4885TBXA2R 97/4885CCR2 2928/4885 |
| US-20070123522-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | LMNA 2110/4885TBXA2R 97/4885CCR2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.